The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion
Abstract
High cholesterol is a major risk factor for cardiovascular disease 1. Currently, no drug lowers cholesterol through directly promoting cholesterol excretion. Human genetic studies have identified that the loss-of-function Asialoglycoprotein receptor 1 (ASGR1) variants associate with low cholesterol and a reduced risk of cardiovascular disease 2. ASGR1 is exclusively expressed in liver and mediates internalization and lysosomal degradation of blood asialoglycoproteins 3. The mechanism by which ASGR1 affects cholesterol metabolism is unknown. Here, we find that Asgr1 deficiency decreases lipid levels in serum and liver by stabilizing LXRα. LXRα upregulates ABCA1 and ABCG5/G8, which promotes cholesterol transport to high-density lipoprotein and excretion to bile and faeces 4, respectively. ASGR1 deficiency blocks endocytosis and lysosomal degradation of glycoproteins, reduces amino-acid levels in lysosomes, and thereby inhibits mTORC1 and activates AMPK. On one hand, AMPK increases LXRα by decreasing its ubiquitin ligases BRCA1/BARD1. On the other hand, AMPK suppresses SREBP1 that controls lipogenesis. Anti-ASGR1 neutralizing antibody lowers lipid levels by increasing cholesterol excretion, and shows synergistic beneficial effects with atorvastatin or ezetimibe, two widely used hypocholesterolaemic drugs. In summary, this study demonstrates that targeting ASGR1 upregulates LXRα, ABCA1 and ABCG5/G8, inhibits SREBP1 and lipogenesis, and therefore promotes cholesterol excretion and decreases lipid levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, this was recently contended by a study reporting Asgr1 deficiency in mice has no effect on hepatic LDLR abundance [88].Instead, this study suggests that reduced plasma LDL-cholesterol in the absence of Asgr1 is due to increased LXRα signaling and enhanced reverse cholesterol efflux.”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [88]
In the citing paper
“The LDLR peptide has an N-terminal ligand binding domain which has high affinity for Apolipoprotein E74,75, as well as Apolipoprotein B (ApoB)76, the main structural components of VLDL/LDL.”
From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [75]
In the citing paper
“These glycosylation sites not only impact LDLR stability and function, but may also affect degradation rates of the LDLR, specifically by ASGR1 (discussed in more detail below), an E3 ligase which recognizes a glycosylated region of LDLR75.”
From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [75]
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Mechanisms and regulation of cholesterol homeostasis
Luo, J., Yang, H., & Song, B.-L. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0190-7 · Cited by 1,980
Self-citationCarbohydrate-Specific Receptors of the Liver
Ashwell, G., & Harford, J. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.002531 · Cited by 1,914
Li, Y., Xu, S., Mihaylova, M. M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., Lefai, É., Shyy, J. Y.-J., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.009 · Cited by 1,840
Self-citationBerge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J. R., Kwiterovich, P. O., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,645
Termination of autophagy and reformation of lysosomes regulated by mTOR
Yu, L., McPhee, C. K., Zheng, L., Mardones, G. A., Rong, Y., Peng, J., Mi, N., Zhao, Y., Liu, Z., Wan, F., et al. (2010) · Nature · doi:10.1038/nature09076 · Cited by 1,544
mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
Peterson, T. R., Sengupta, S., Harris, T. E., Carmack, A. E., Kang, S. A., Balderas, E., Guertin, D. A., Madden, K. L., Carpenter, A. E., Finck, B. N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.034 · Cited by 1,293
Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1
Wang, S., Tsun, Z.-Y., Wolfson, R. L., Shen, K., Wyant, G. A., Plovanich, M., Yuan, E. D., Jones, T. D., Chantranupong, L., Comb, W. C., et al. (2015) · Science · doi:10.1126/science.1257132 · Cited by 865
Repa, J. J., Berge, K. E., Pomajzl, C., Richardson, J. A., Hobbs, H. H., & Mangelsdorf, D. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109927200 · Cited by 852
AMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth Control
González, A., Hall, M. N., Lin, S.-C., & Hardie, D. G. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.015 · Cited by 797
Cited by
Sorted by citations
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01439-y · Cited by 295
Xiao, J., Wang, S., Chen, L., Ding, X., Dang, Y., Han, M., Zheng, Y., Shen, H., Wu, S., Wang, M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.021 · Cited by 220
Lysosomal control of senescence and inflammation through cholesterol partitioning
Roh, K., Noh, J., Kim, Y., Jang, Y., Kim, J., Choi, H., Lee, Y., Ji, M., Kang, D., Kim, M.-S., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00747-5 · Cited by 149
Cui, D., Yu, X., Guan, Q., Shen, Y., Liao, J., Liu, Y., & Su, Z. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00321-3 · Cited by 126
Self-citationLiu, T., Kong, X., Qiao, J., & Wei, J. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103787 · Cited by 112
Self-citation
Metadata
- Authors
- Wang, J.-Q., Li, L.-L., Hu, A., Deng, G., Wei, J., Li, Y.-F., Liu, Y.-B., Lu, X.-Y., Qiu, Z.-P., Shi, X.-J., Zhao, X., Luo, J., & Song, B.-L.
- Affiliations
- Wuhan University (CN)
- Corresponding author
- Song, Bao-Liang
- ORCID
- Venue
- Nature
- Published
- 2022-08-03
- Volume
- 608
- Issue
- 7922
- Pages
- 413-420
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4289638327
- Semantic Scholar
- 2c228e8e3bb08f6cb71f8c0237f1ccbab6eb5db0
- Cited by
- 188
- References
- 39
- Citations by year
- 2026: 51 · 2025: 53 · 2024: 45 · 2023: 31 · 2022: 7
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- ASGR1, asialoglycoprotein receptor, cholesterol excretion, hypercholesterolemia, liver X receptor alpha, ABCA1, ABCG5/G8, SREBP1, lipogenesis, AMPK, mTORC1, lysosomal degradation, endocytosis, high-density lipoprotein, cardiovascular disease, neutralizing antibodies, ezetimibe, atorvastatin
- MeSH terms
- Atorvastatin, Ezetimibe, ATP Binding Cassette Transporter, Subfamily G, Member 5, ATP Binding Cassette Transporter, Subfamily G, Member 8, Liver X Receptors, Mechanistic Target of Rapamycin Complex 1, Asialoglycoproteins, Cardiovascular Diseases, Cholesterol, Drug Synergism, Endocytosis, Humans, Lipids, Liver, Lysosomes, BRCA1 Protein, Asialoglycoprotein Receptor, Ubiquitin-Protein Ligases, Lipid Metabolism, Sterol Regulatory Element Binding Protein 1, AMP-Activated Protein Kinases, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
